The effect of TGF-β2 on human trabecular meshwork extracellular proteolytic system

Experimental Eye Research

Volumn 77, Issue 6, 2003, Pages 757-765

  Fuchshofer, Rudolf ^a   Welge Lussen, Ulrich ^b   Lütjen Drecoll, Elke ^a,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Extracellular matrix; Glaucoma; Growth factors; Metalloproteinases; Trabecular meshwork

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; NEUTRALIZING ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA2; GELATIN; MATRIX METALLOPROTEINASE; TGFB2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

AGED; AQUEOUS HUMOR; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NORTHERN BLOTTING; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TRABECULAR MESHWORK; WESTERN BLOTTING; ZYMOGRAPHY; ADULT; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; GELATIN; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRABECULAR MESHWORK; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

EID: 0242594633     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4835(03)00220-3     Document Type: Article

References (41)

1. Acott T.S. Trabecular extracellular matrix regulation. Drance S.M., Van Buskirk E.M., Neufeld A.H. Pharmacology of Glaucoma. 1992;125-127 Williams and Wilkins, Baltimore, MD.
2. Acott T.S. Biochemistry of aqueous humor outflow. Kaufman P., Mittag T. Textbook of Ophthalmology. Vol. 7:1994;1.47-41.78 Mosby, London.
3. Acott T.S., Wirtz M.K. Biochemistry of aqueous outflow. Ritch R., Shields M., Krupin T. The Glaucomas. Vol. 1:1996;281-305 Mosby Year Book, St. Louis, MO.
4. Alexander J.P., Samples J.R., Acott T.S. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr. Eye Res. 17:1998;276-285.
5. Alexander J.P., Samples J.R., Van Buskirk E.M., Acott T.S. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 32:1991;172-180.
6. Babizhayev M.A., Brodskaya M.W. Fibronectin detection in drainage outflow system of human eyes in ageing and progression of open-angle glaucoma. Mech. Age. Dev. 47:1989;145-157.
7. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb. Haemost. 82:1999;298-304.
8. Border W.A., Okuda S., Languino L.R., Sporn M.B., Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 346:1990;371-374.
9. Bradley J.M., Kelley M.J., Zhu X., Anderssohn A.M., Alexander J.P., Acott T.S. Effects of mechanical stretching on trabecular matrix metalloproteinases. Invest. Ophthalmol. Vis. Sci. 42:2001;1505-1513.
10. Bradley J.M., Vranka J., Colvis C.M., Conger D.M., Alexander J.P., Fisk A.S., Samples J.R., Acott T.S. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci. 39:1998;2649-2658.
11. Eitzman D.T., Ginsburg D. Of mice and men. The function of plasminogen activator inhibitors (PAIs) in vivo. Adv. Exp. Med. Biol. 425:1997;131-141.
12. Gottanka J., Johnson D.H., Martus P., Lutjen-Drecoll E. Severity of optic nerve damage in eyes with POAG is correlated with changes in the trabecular meshwork. J. Glaucoma. 6:1997;123-132.
13. Kaikita K., Fogo A.B., Ma L., Schoenhard J.A., Brown N.J., Vaughan D.E. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 104:2001;839-844.
14. Kinoshita T., Sato H., Takino T., Itoh M., Akizawa T., Seiki M. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res. 56:1996;2535-2538.
15. Leak L.V., Saunders M., Day A.A., Jones M. Stimulation of plasminogen activator and inhibitor in the lymphatic endothelium. Microvasc. Res. 60:2000;201-211.
16. Lutjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog. Ret. Eye Res. 18:1998;91-119.
17. Lutjen-Drecoll E., Rohen J.W. Morphology of aqueous outflow pathways in normal and glaucomatous eyes. Ritch R., Shields M., Krupin T. 2nd Ed. The Glaucomas. Vol. 1:1996;89-124 Mosby Year Book, St. Louis.
18. Lutjen-Drecoll E., Shimizu T., Rohrbach M., Rohen J.W. Quantitative analysis of plaque material in the inner-and outer wall of Schlemm's canal in normal- and glaucomatous eyes. Exp. Eye Res. 42:1986;443-455.
19. Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S., Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. Embo J. 16:1997;2319-2332.
20. Monea S., Lehti K., Keski-Oja J., Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J. Cell Physiol. 192:2002;160-170.
21. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378:1997;151-160.
22. Oda T., Jung Y.O., Kim H.S., Cai X., Lopez-Guisa J.M., Ikeda Y., Eddy A.A. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 60:2001;587-596.
23. Okumura Y., Sato H., Seiki M., Kido H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett. 402:1997;181-184.
24. Park J.K., Tripathi R.C., Tripathi B.J., Barlow G.H. Tissue plasminogen activator in the trabecular endothelium. Invest. Ophthalmol. Vis. Sci. 28:1987;1341-1345.
25. Picht G., Welge-Luessen U., Grehn F., Lutjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch. Clin. Exp. Ophthalmol. 239:2001;199-207.
26. Rohen J.W., Futa R., Lutjen-Drecoll E. The fine structure of the cribriform meshwork in normal and glaucomatous eyes as seen in tangential sections. Invest. Ophthalmol. Vis. Sci. 21:1981;574-585.
27. Rohen J.W., Witmer R. Electron microscopic studies on the trabecular meshwork in glaucoma simplex. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 183:1972;251-266.
28. Rondeau E., Sraer J., Schleuning W. The renal plasminogen activating system. Schlondorff D., Bonventre J. Molecular Nephrology: Kidney Function in Health and Diseases. 1995;699-715 Marcel Dekker, New York.
29. Samples J.R., Alexander J.P., Acott T.S. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest. Ophthalmol. Vis. Sci. 34:1993;3386-3395.
30. Sawdey M., Podor T.J., Loskutoff D.J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J. Biol. Chem. 264:1989;10396-10401.
31. Shuman M.A., Polansky J.R., Merkel C., Alvarado J.A. Tissue plasminogen activator in cultured human trabecular meshwork cells. Predominance of enzyme over plasminogen activator inhibitor. Invest. Ophthalmol. Vis. Sci. 29:1988;401-405.
32. Siegner A., May C.A., Welge-Lussen U.W., Bloemendal H., Lutjen-Drecoll E. alpha B-crystallin in the primate ciliary muscle and trabecular meshwork. Eur. J. Cell Biol. 71:1996;165-169.
33. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270:1995;5331-5338.
34. Tripathi R.C., Li J., Chan W.F., Tripathi B.J. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp. Eye Res. 59:1994;723-727.
35. Tripathi R.C., Tripathi B.J., Park J.K. Localization of urokinase-type plasminogen activator in human eyes: an immunocytochemical study. Exp. Eye Res. 51:1990;545-552.
36. Welge-Lussen U., Eichhorn M., Bloemendal H., Lutjen-Drecoll E. Classification of human scleral spur cells in monolayer culture. Eur. J. Cell Biol. 75:1998;78-84.
37. Welge-Lussen U., May C.A., Eichhorn M., Bloemendal H., Lutjen-Drecoll E. AlphaB-crystallin in the trabecular meshwork is inducible by transforming growth factor-beta. Invest. Ophthalmol. Vis. Sci. 40:1999;2235-2241.
38. Welge-Lussen U., May C.A., Lutjen-Drecoll E. Induction of tissue transglutaminase in the trabecular meshwork by TGF-beta1 and TGF-beta2. Invest. Ophthalmol. Vis. Sci. 41:2000;2229-2238.
39. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Nat. Acad. Sci. USA. 90:1993;1814-1818.
40. Yamamoto T., Noble N.A., Cohen A.H., Nast C.C., Hishida A., Gold L.I., Border W.A. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 49:1996;461-469.
41. Yamamoto T., Noble N.A., Miller D.E., Border W.A. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int. 45:1994;916-927.